Sponsored
DMCA
Novo Nordisk CEO to step down amid market challenges and stock plunge
Novo Nordisk's CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, exceeding 50% since June 2024. Increased competition from compounded versions of Ozempic and Wegovy, along with Eli Lilly's Zepbound gaining market share, contributed to the decision.
नेपाली
हिन्दी
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
Arabic
French
অসমীয়া
বাংলা